Skip to main content
Fig. 1 | Genome Medicine

Fig. 1

From: Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial

Fig. 1

Clinicopathological features in association with response to pembrolizumab. S represents each patient’s identification number. A Swimmer plot for enrolled patients (n = 60). Each lane represents a single patient’s data. B Waterfall plot of response to pembrolizumab. The Y-axis represents the percentage of maximum tumor reduction assessed according to RECIST 1.1 criteria. The lower dotted line represents tumor reduction of 30% per RECIST, which defines PR (responder). Patients with bars in blue (PD) and yellow (SD) were determined to be non-responders. C Univariate analysis to identify clinicopathological features associated with response to pembrolizumab. Odds ratio and p value for each feature were computed via Fisher’s exact test. The size of the circle represents the number of samples. D–F Tumor reduction after pembrolizumab treatment in three responders who have available PD-L1 status by immunohistochemistry (IHC) (upper panel). H&E staining and PD-L1 positivity for the three responders (lower panel). PR, partial response; SD, stable disease; PD, progressive disease; CPS, combined positive score, AFP, alpha-fetoprotein; NLR, neutrophil-to-lymphocyte ratio

Back to article page